Navigation Links
Gonorrhea – Godzilla Of STD

Gonorrhea, the common sexually transmitted disease has evolved to become resistant to all classes of antibiotics save one, say alarmed health professionals. //

Accordingly, the U.S. Centers for Disease Control and Prevention (CDC) has said that it will no longer recommend the use of fluoroquinolones due to the emergence of drug-resistant strains in recent years that subdue them.

Yet, hope remains as there is no indication so far that the strains that cause gonorrhea have become or are becoming resistant to the remaining class of antibiotics, known as cephalosporins.

Voicing his concerns, Dr. John Douglas, director of the CDC ’s Division of Sexually Transmitted Diseases Prevention, was quoted: “Although the cephalosporins offer several potential options for treating gonorrhea, the lack of additional classes of antibiotics is a serious concern. There are currently no new drugs for gonorrhea in the drug development pipeline.”

Experts note that this form of resistant gonorrhea previously common among homosexual and bisexual men, are now seen among heterosexual men.

The CDC has released data indication that gonorrhea has become resistant to fluoroquinolones.

Douglas added:” While we have not seen any significant resistance to cephalosporins to date, any emerging resistance would be a significant public health concern. Clearly, there is an urgent need for new, effective medicines to treat gonorrhea as we are running out of options to treat this serious disease.”

The CDC recommends an injectable drug called ceftriaxone, sold by Roche Pharmaceuticals as Rocephin, to treat genital, anal and throat gonorrhea.



'"/>




Page: 1

Related medicine news :

1. Gonorrhea Found To Increase Cancer Risk
2. Gonorrhea and Male Bladder Cancer-Ties That Bound
3. Rare Gonorrhea Strain Makes Diagnosis Very Difficult
4. Scientists Concerned About Gonorrhea’s Drug Resistanc
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/26/2017)... , ... May 26, 2017 , ... Yisrayl Hawkins, Pastor ... publication this week that is focusing on the Peace Agreements being discussed by President ... East sprint in a race to try to speed up peace talks in the ...
(Date:5/26/2017)... ... ... Lowe acts as host and helps educate and inform the public using the “Informed” ... reconnect with America as it explores some of the best places to hike and ... inventive new place for a family vacation, and have discovered hiking. Many will agree ...
(Date:5/26/2017)... ... May 26, 2017 , ... “When the Stars Lead Home”: ... the creation of published author Laura Weigel Douglas, an avid reader who lives in ... house that sometimes feels like Green Hills Adventure Camp. She couldn’t be more grateful. ...
(Date:5/26/2017)... ... May 26, 2017 , ... ... recipient of proceeds from its 14th Annual Clays for Kids fundraiser, to be ... 30, Bennett, Colorado. , As part of BluSky’s partnership with The Adoption ...
(Date:5/26/2017)... ... ... “Cactus Jack: Against All Odds”: the story of Coach Cactus Jack and the impact ... the creation of published author, Walter Hubbard, a retired wildlife and fisheries biologist and ... Walter. Walter and Jane have three adult children and a granddaughter. Walter ...
Breaking Medicine News(10 mins):
(Date:5/23/2017)... May 23, 2017  Leaf Healthcare, recognized for ... devices for pressure ulcer prevention, will unveil its ... of Critical Care Nurses, National Teaching Institute and ... The Leaf Patient Monitoring System is the ... hospital environment.  The system seamlessly tracks patient movement ...
(Date:5/22/2017)... , May 22, 2017  As the specialty ... whole continue to make the revolutionary shift from ... important for ensuring positive patient outcomes and shaping ... are shifting focus away from clinical trials and ... of long-term specialty drug therapy utilization in precise ...
(Date:5/18/2017)... , May 17, 2017  Bayer announced today that ... will be presented at the 53 rd Annual ... taking place June 2-6 in Chicago ... ASCO span prostate, colorectal, liver and thyroid cancers, as ... the Phase II CHRONOS-1 trial of copanlisib in patients ...
Breaking Medicine Technology: